Biosimilar Antibodies
Our biosimilar antibodies are for research use only and are ideal tools for drug research studies and assay development.
Biosimilar Antibodies
Our biosimilar antibodies are validated for a number of research applications such as flow cytometry, blocking/neutralizing, and immunocytochemistry.
Chemsis biosimilar antibodies are for research use only and are developed with recombinant antibody technology using the same sequence as the original therapeutic (reference) antibody. Biosimilars are a cost-effective alternative for assay development, facilitating development and validation of novel therapeutics.
Biosimilar Antibodies for Research Use
Our biosimilar antibodies are made using the identical sequence of the original therapeutic product, with no alteration or truncation, including variable region and Fc domain. Research use only (RUO) biosimilar antibodies offer substantial value to biomedical research as they offer cost-effective alternatives for studying and characterizing specific disease targets in critical fields of study, including immuno-oncology, autoimmunity, and inflammatory disease research.
Featured Biosimilar Antibodies
| Target | Biosimilar Antibody |
| CD3 | Teplizumab |
| CD20 | Rituximab |
| CD52 | Alemtuzumab |
| EGFR | Cetuximab |
| ErbB2/Her2 | Trastuzumab |
| IL-5 | Mepolizumab |
| IL-6R alpha | Tocilizumab |
| Integrin alpha 4 beta 1 | Natalizumab |
| Integrin alpha 4 beta 7/LPAM-1 | Vedolizumab |
| PD-1 | Pembrolizumab |
| TNF-alpha | Adalimumab |
| VEGF | Bevacizumab |
| vWF | Caplacizumab |
